Monitor for the appointment of a new independent director and for clinical trial milestones for mizagliflozin in PBH and gastroparesis, which will be the primary value drivers for this clinical-stage biotech.
Price Chart
Executive Summary
Vogenx announced that board member Richard Gorman will become Chief Commercial Officer effective October 12, 2026, resigning from the board and all committees. The move adds a 30-year biopharmaceutical commercial leader to the management team as the company advances its lead candidate mizagliflozin toward later-stage development following its August 2026 IPO.
Key Facts
- Richard Gorman resigns from the Board of Directors and all committees effective October 12, 2026, to become Chief Commercial Officer.
- Gorman has 30 years of life sciences commercial experience, supporting more than 25 product launches with peak sales ranging from $350 million to over $3 billion.
- The company will conduct a search to identify a new independent director to join the Board.
- Gorman will lead commercial operations and corporate strategy, including market development for post-bariatric hypoglycemia (PBH) and gastroparesis.
Financial Impact
No financial figures disclosed; the appointment is a personnel change with no immediate revenue or cost impact.
Risk Factors
- Clinical-stage company with no approved products; mizagliflozin remains in development with regulatory and trial risks.
- Loss of an independent board seat reduces board independence until a replacement is found.
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001185185-26-004679 |
| Document: vogenxex99-1.htm | 0001185185-26-004679 |
| Document: 0001185185-26-004679-index-headers.html | 0001185185-26-004679 |
| Document: 0001185185-26-004679-index.html | 0001185185-26-004679 |
| Document: 0001185185-26-004679.txt | 0001185185-26-004679 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $17.56 | awaiting T+20 | — | $17.34 (−1.25%) |
Aug 17, 2026 10w ago | Press Release | $15.75 $32.21 | ▲ +104.51% | ▲ +106.49% | $17.34 (+10.10%) |
Aug 11, 2026 10w ago | 3 | $13.00 $29.86 | ▲ +129.69% | ▲ +131.59% | $17.34 (+33.38%) |
Aug 11, 2026 10w ago | 3 | $13.00 $29.86 | ▲ +129.69% | ▲ +131.59% | $17.34 (+33.38%) |
Aug 10, 2026 11w ago | S-1/A | — | awaiting T+20 | — | — |
Jul 29, 2026 12w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers